Physician profile
Thomas Christopher Sanchez
NPI 1841395522
$2,868.36
in general payments reported to CMS, 2019-2025
39 companies · $461 in 2025
The $461 reported for 2025 was more than what 90% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $106 · 2021: $968 · 2022: $125 · 2023: $355 · 2024: $296 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,111.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $688.55 | 2021 | |
| Abbvie INC. | $287.66 | 2021-2025 | Ubrelvy |
| Nevro Corp. | $200.99 | 2019-2020 | |
| Argenx US, INC. | $147.37 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Teva Pharmaceuticals USA, INC. | $130.86 | 2019-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $118.11 | 2023-2025 | |
| Globus Medical, INC. | $77.99 | 2025 | Senza |
| Genzyme Corporation | $66.68 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $65.27 | 2019 | |
| Neurelis, INC. | $64.62 | 2023-2024 | Valtoco |
| Sunovion Pharmaceuticals INC. | $64.04 | 2019-2020 | |
| Lundbeck LLC | $61.40 | 2024-2025 | Rexulti, Vyepti |
| Greenwich Biosciences, INC. | $55.66 | 2019-2021 | |
| Allergan, INC. | $55.43 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $55.21 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $55.20 | 2024-2025 | Leqembi, Tysabri, Vumerity |
| Emd Serono, INC. | $52.85 | 2023-2024 | Mavenclad |
| Lilly USA, LLC | $48.80 | 2023-2025 | Emgality, Zepbound, Mounjaro |
| Avadel Cns Pharmaceuticals, LLC | $46.27 | 2024-2025 | Lumryz |
| Amylyx Pharmaceuticals, INC. | $44.33 | 2023 | Relyvrio |
| Amgen INC. | $39.94 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $37.68 | 2019-2021 | |
| Genentech USA, INC. | $36.52 | 2023 | Ocrevus |
| Jazz Pharmaceuticals INC. | $35.71 | 2019-2025 | |
| Ge Healthcare | $34.58 | 2019 | |
| Acadia Pharmaceuticals INC | $29.80 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $26.91 | 2021 | |
| Ucb, INC. | $26.58 | 2023 | |
| Merz Pharmaceuticals, LLC | $24.96 | 2025 | Inbrija |
| Tms Neurohealth Centers INC. | $24.76 | 2025 | Tms Neurohealth Centers INC. |
| Sarepta Therapeutics, INC. | $23.82 | 2019 | |
| Vanda Pharmaceuticals INC. | $21.22 | 2025 | Ponvory |
| Banner Life Sciences, LLC | $20.60 | 2024 | |
| Pfizer INC. | $19.62 | 2024 | |
| Grt US Holding, INC. | $19.10 | 2022 | |
| Si-Bone, INC. | $18.00 | 2022 | |
| Neurocrine Biosciences, INC. | $16.70 | 2023 | Ingrezza |
| Inspire Medical Systems, INC. | $13.08 | 2023 | Inspire |
| Amneal Pharmaceuticals LLC | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.